AVEIR^™ AR2 Atrial
Leadless Pacemaker

Atrial Leadless Pacemakers - Exclusively from Abbott

About

Why AVEIR AR2 Atrial Leadless Pacemaker

A Complete Leadless Solution Includes Atrial Pacing

In patients with sinus node dysfunction (SND) and preserved atrioventricular (AV) conduction, the AVEIR AR2 Atrial Leadless Pacemaker offers a more physiological approach to pacing by initiating atrial activation and maintaining AV synchrony through the native conduction system¹ while helping reduce the risk of atrial fibrillation (AF), heart failure (HF) and pacing-induced cardiomyopathy.^2-5

Now With Increased Longevity

Expanding Abbott’s leadless platform, the AVEIR AR2 Atrial LP with enhanced longevity is designed for long-term therapy and future adaptability.

AVEIR AR2 LP offers these key benefits over AVEIR AR LP without increasing device size:

25% more battery longevity in all single and dual chamber pacing modes^6,*
Over 10 years of projected battery life in AAI(R) or AAI(R)+VVI^† pacing modes⁶

Upgradeable to Dual-Chamber Pacing System

When paired with the AVEIR VR Ventricular LP, the AVEIR AR2 Atrial LP forms the AVEIR DR Dual Chamber System, which can be programmed to DDD(R) or AAI(R)+VVI.

For patients with complete heart block, DDD(R) pacing is available by enabling implant-to-implant (i2i^TM) communication between the devices to provide high AV synchrony.⁷

For patients with sinus node dysfunction that might benefit from ventricular back-up pacing, AAI(R)+VVI is available with implant-to-implant (i2i) communication turned off, providing increased battery life for both devices.⁶

AVEIR AR Atrial LP Clinical Outcomes

Review the Clinical Evidence

ELECTRICAL PERFORMANCE SUCCESS RATE AT 3 MONTHS for patients with acceptable atrial device pacing capture threshold (≤ 3 V at 0.4 ms) and sensing amplitude (≥ 1 mV)^**,7

95.2% 3-month atrial composite success rate with modified sensing criteria (≥ 0.5 mV)^**,8

FREEDOM FROM COMPLICATIONS AT 3 MONTHS.⁷ The inclusion of arrhythmias as a safety endpoint increased the overall incidence of complications compared with other studies of leadless pacemakers, which excluded arrhythmias from the endpoint.

**Multiple imputation used for missing data

Discover the Clinical Evidence

At Heart Rhythm 2025, Dr. Rajesh Banker shares a tailored approach to treating SND patients with AVEIR Leadless Pacemakers (LPs), from AAI(R) to AAI(R)+VVI pacing. This session highlights how the AVEIR DR Dual Chamber LP System—featuring both atrial (AVEIR AR Atrial LP) and ventricular (AVEIR VR Ventricular LP) leadless pacemakers—leverages implant-to-implant (i2i) communication to deliver synchronized DDD(R) pacing when needed. Learn how this minimally invasive system offers enhanced longevity, personalized therapy, and a revolutionary step forward in cardiac rhythm management.

View the presentation

Resources

Recent Blogs

Exploring AAI Pacing - Initial Real-World Data on AVEIR™ AR Atrial Leadless Pacemaker

Real-world data demonstrated that the combination of AAI pacing and leadless pacemaker technology offers a safer, more efficient treatment of sick sinus syndrome (SSS) over transvenous pacing methods.

AAI or DDD – Which Pacing Mode is Right for Patients with Sick Sinus Syndrome?

Explore the ongoing debate between AAI and DDD pacing for sick sinus syndrome (SSS). Learn how guidelines, trials, and innovations like leadless pacemakers, such as the AVEIR™ AR Atrial LP, influence clinical decisions to improve outcomes for SSS patients.

Unmatched Innovation: Setting the Pace with FDA-Approved AVEIR™ AR Atrial Leadless Pacemaker

With its innovative features and promising early clinical evidence, AVEIR™ Atrial AR LP, only from Abbott, is poised to revolutionize leadless pacing by providing patients across the U.S. with access to advanced medical care.

View AVEIR AR Atrial LP in Action

Reexamine the Therapy Choice for SND Patients (2024)

Presentation at Heart Rhythm 2024 by Monica Lo, MD, FHRS, FACC

Watch Presentation

Sinus Node Dysfunction Case Studies

View Case Studies

Minimizing for Maximum Benefit: An Illustrative Case-Series of Atrial Only Leadless Pacing

View the Clinical Evidence

Upgradeable System

Patient therapy can be tailored by implanting an atrial device alone, or both atrial and ventricular devices together for dual chamber support. The option to upgrade over time allows you to meet your patient’s needs today and adapt to common disease progression later.

Treatment Option 1: Start with the Atrial Device.

Treat atrial arrhythmia and sinus node dysfunction today.

Add a ventricular device for heart block later.

i2i™ communication is enabled.

Activate dual chamber pacing therapy DDD(R) via i2i communication.

Treatment Option 2: Start with a dual chamber DDD(R) system.

Start with a dual chamber system device.

Turn off Beat-to-Beat communications to enable independent single chamber pacing for each device.

Treat SND patients today with AAI(R)+VVI pacing in the case of rare intermittent AV block.

Up to 70% increase in atrial device longevity with AAI(R)+VVI versus DDD(R)^6,***
Minimized/back-up ventricular pacing in the case of rare intermittent AV block

*AVEIR AR2 LP model LSP203A compared to predecessor AVEIR AR LP LSP201A: AAI(R) at 1.5 V, 300 ohms, 0.4 ms, 50 bpm, 100% atrial pacing. DDD(R) at: 1.5 V, 300 ohms, 0.4 ms, 50 bpm, 50% atrial pacing, i2i setting 4/4.

† Note: AAI(R)+VVI mode should not be used in patients without intact AV node conduction, or with chronic atrial fibrillation or atrial flutter.

*** 1.5V, 0.4 ms, 60 bpm, 300 ohms, 100% A pacing, 10% V pacing, i2i™ settings = 4 / 4

Partnering with You to Personalize Care

Sign up to hear about our technology, education opportunities, and more.

Join Our Email List

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.

Visit the Abbott CRM Blog

For additional information about specific MR Conditional, including warnings, precautions, adverse conditions to MRI scanning and potential adverse events, please refer to the MRI-Ready Leadless Systems Manual at medical.abbott/manuals or check our MRI-Ready resources at cardiovascular.abbott/mriready

REFERENCES

Rosenqvist M. Atrial pacing for sick sinus syndrome. Clin Cardiol. 1990 Jan;13(1):43-7. doi: 10.1002/clc.4960130108. PMID: 2404646.
Kim WH, Joung B, Shim J, et al. Long-term outcome of single-chamber atrial pacing compared with dual-chamber pacing in patients with sinus-node dysfunction and intact atrioventricular node conduction. Yonsei Medical Journal. 2010;51(6):832-837. doi: 10.3349/ymj.2010.51.6.832.
Fored C, Granath F, Gadler F, et al. Atrial vs. dual-chamber cardiac pacing in sinus node disease: a register-based cohort study. Europace. 2008;10(7):825-831. https://doi.org/10.1093/europace/eun118
Healey JS, Toff WD, Lamas GA, et al. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation. 2006;114(1):11-17. doi: 10.1161/CIRCULATIONAHA.105.610303.
Masumoto H, Ueda Y, Kato R, et al. Long-term clinical performance of AAI pacing in patients with sick sinus syndrome: a comparison with dual-chamber pacing. Europace. 2004;6(5):444-450. doi: 10.1016/j.eupc.2004.05.003.
AVEIR Leadless Pacemakers and Delivery Catheter IFU. ARTEN600361108.
Knops, Reinoud E., et al. “A Dual- Chamber Leadless Pacemaker.” New England Journal of Medicine (2023). DOI: 10.1056/ NEJMoa2300080.
Cantillon, Daniel, et al. (2023, May 19-21). Percutaneous implantation of a dual chamber leadless cardiac pacemaker system with bidirectional communication for atrioventricular synchrony. [Conference presentation]. Heart Rhythm Society 2023, New Orleans, USA.

Manuals & Resources

Cardiovascular Products

Reimbursement & Coding